Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Breaking News

Israel’s ReWalk Plans IPO After ‘Ecoskeleton’ Success

The Israeli company ReWalk Robotics will sell public shares for the first time for a device that enables people with spinal cord injuries to stand and walk.

The company, which changed its name from Argo Medical Technologies to the name of its major product, announced this week that it will make an initial public offering on the NASDAQ next month.

The ReWalk device, a 44-pound exoskeleton that allows individuals with spinal cord injuries to walk, stand and sit with minimal exertion, was featured in 2010 on the popular television drama “Glee” while undergoing clinical trials in the United States.

The company recently received approval for the device from the U.S. Food and Drug Administration for home use. It is already in use in Europe.

The ReWalk, developed by Argo and released in September 2012, is the brainchild of Amit Goffer, an Israeli computer scientist and inventor who became paralyzed after a 1997 car accident. Although he cannot use the ReWalk himself because he lacks the use of his arms, he began designing the device with the help of a $50,000 grant from the Israeli government because he was frustrated at the lack of alternatives to a wheelchair.

The device functions through motors attached to the legs that can propel a disabled person at a slow walking speed. A tilt sensor, the same technology used on Segway electric transporters, can sense whether the user wants to move forward or back, stand or sit. Poles are used for added support.

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse.

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

—  Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.